Risk-based validation is an approach in which the extent andrigor of validation activities are proportionate to the intended use, complexity, and potential impact of a system, function, or change.
The process begins with understanding how the systemsupports the regulated process. Risk assessment then considers what could happen if the system fails to perform as intended, including potential effects on patient safety, product quality, data integrity, and compliance.
The assessment should consider relevant factors such as severity, likelihood, and the ability to detect a failure before harm occurs. Risk-assessment results guide the required controls, depth of testing, level of documentation, and extent to which supplier evidence can be leveraged.
The objective is not simply to perform fewer tests. It is todirect effort toward the functions and failure scenarios that require greater assurance and maintain traceability between risks, requirements, controls, testing, and results.
Risk-based validation is particularly important forfrequently updated cloud and SaaS applications. Organizations can assess changes, identify affected functions and risks, and perform targeted assurance activities.
Frequently Asked Questions
What determines risk in risk-based validation?
Risk is determined through an approved methodology that considers intended use and the potential consequences of failure. Factors may include patient safety, product quality, data criticality, regulatory impact, severity, likelihood, detectability, and existing controls.
Can low-risk systems skip validation entirely?
A system within GxP scope should be subject to assurance activities appropriate to its intended use and risk. A documented assessment may conclude that a system is outside GxP scope, but low risk does not automatically mean that no evidence is required.
Is risk-based validation accepted outside the FDA’s jurisdiction?
Risk-based life-cycle approaches are reflected in GAMP 5 andEU GMP Annex 11, as well as in FDA guidance. Each organization should evaluate the specific requirements applicable to its products, systems, and markets.
What is a common weakness in risk-based validation?
One common weakness is completing the risk assessment after the validation scope and testing strategy have already been decided. Risk assessment should inform assurance decisions rather than retrospectively justify them.